NCT07917403 Study NRPT Feasibility in Knee Osteoarthritis
| NCT ID | NCT07917403 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, San Diego |
| Condition | Knee Osteoarthristis |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-12 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2026-12 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To Evaluate Feasibility and Exploratory Clinical and Biomarker Signals of NRPT in Adults with Knee Osteoarthritis
Eligibility Criteria
Inclusion Criteria: 1. Provision of signed and dated informed consent form. 2. Stated willingness to comply with all study procedures and availability for the planned 14-week duration of participation. 3. Adults aged 18 to 80 years (inclusive) at the time of consent, of any sex. 4. Unilateral symptomatic radiographic KOA defined as Kellgren-Lawrence (KL) grade 2 or 3 in the tibiofemoral joint of the index knee, as determined from a standing knee radiograph obtained within the prior 12 months or at Screening. 5. Knee pain in the index knee with a Visual Analogue Scale (VAS) score of 20-80 (on a 0-100 scale) over the prior 7 days at Screening. 6. No changes in OA-directed therapy (including analgesics, NSAIDs, topical therapies, or non-pharmacologic regimens) in the 3 months prior to Screening. 7. Agreement to refrain from vitamin B3-containing supplements (nicotinic acid, nicotinamide, nicotinamide riboside) and any multivitamin containing these ingredients for at least 14 days prior to Baseline and throughout the duration of the study. 8. Ability to take oral capsule medication and willingness to adhere to the prescribed NRPT regimen. 9. Agreement to adhere to lifestyle considerations specified in Section 5.3 throughout the study. Exclusion Criteria: 1. Prior surgical intervention on the index knee (including arthroscopy, ligament reconstruction, osteotomy, or joint replacement). 2. Severe radiographic knee disease (KL grade 4) in the index knee. 3. Bilateral symptomatic radiographic KOA (i.e., KL grade ≥2 with symptomatic pain in both knees). 4. Diagnosis of inflammatory arthritis (including but not limited to rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or crystal arthropathy of the index knee). 5. Use of systemic corticosteroids, intra-articular corticosteroid or hyaluronic acid injection in the index knee, chondroitin, glucosamine, or other polyphenol-containing supplements (including resveratrol, curcumin) within the 3 months prior to Screening. 6. Self-reported substantive change in physical activity level (initiation of a new exercise program or cessation of regular activity) within the 3 months prior to Screening. 7. Pregnancy, lactation, or planning pregnancy during the study period. Women of childbearing potential must have a negative serum or urine pregnancy test at Screening. 8. Severe or uncontrolled comorbid conditions that, in the opinion of the investigator, would compromise participant safety or interpretability of study data, including but not limited to: uncontrolled diabetes mellitus (HbA1c \>9.0% or requiring recent insulin initiation); active cardiovascular disease (myocardial infarction, unstable angina, decompensated heart failure, or stroke within 6 months); severe chronic kidney disease (eGFR \<30 mL/min/1.73 m²); active liver disease or AST/ALT \>2.5× the upper limit of normal; active malignancy (other than non-melanoma skin cancer) within 5 years; or active substance use disorder. 9. Known allergy or hypersensitivity to nicotinamide riboside, pterostilbene, resveratrol, or any excipient of Basis®. 10. Concurrent participation in another interventional clinical trial or use of an investigational agent within 30 days prior to Screening. 11. Any other condition that, in the opinion of the investigator, would interfere with the participant's ability to comply with the protocol or with the safety or scientific integrity of the study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07917403 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Knee Osteoarthristis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07917403 currently recruiting?
Yes, NCT07917403 is actively recruiting participants. Contact the research team at mguma@ucsd.edu for enrollment information.
Where is the NCT07917403 trial being conducted?
This trial is being conducted at San Diego, United States.
Who is sponsoring the NCT07917403 clinical trial?
NCT07917403 is sponsored by University of California, San Diego. The trial plans to enroll 30 participants.